Crh
Smith-Lemli-Opitz Syndrome
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Smith-Lemli-Opitz Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cholesterol Suspension University of Colorado, Denver | Phase 2 | BB |
SIMVASTATIN Oregon Health and Science University | Phase 2 | B |
CHOLALIC ACID University of Nebraska | Phase 1/2 | CCC |
Lovastatin Northwestern University | Phase 2 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →